AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 12

Date	Insider	Role	Type	Shares	Price	Value	Chg%
Nov 29, 2018	Armistice Capital, LLC56	10% Owner	Buy	77,803	$3.51	$272,863.77	+0.4%
Nov 26, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	50,000	$3.59	$179,407.00	+0.3%
Nov 20, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	49,100	$3.61	$177,292.62	+0.3%
Nov 15, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	31,314	$3.85	$120,577.82	+0.2%
Oct 31, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	5,986	$3.92	$23,481.35	-
Oct 29, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	107,800	$3.95	$425,512.48	+0.6%
Oct 24, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	125,800	$4.13	$519,064.36	+0.7%
Oct 9, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	29,600	$4.34	$128,404.61	+0.2%
Sep 27, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	20,400	$4.64	$94,628.59	+0.1%
Aug 17, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	1,000,000	$3.91	$3,910,000.00	+6.1%